1. Home
  2. SCSC vs GERN Comparison

SCSC vs GERN Comparison

Compare SCSC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ScanSource Inc.

SCSC

ScanSource Inc.

HOLD

Current Price

$40.38

Market Cap

909.7M

Sector

Technology

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.39

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCSC
GERN
Founded
1992
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
909.7M
900.1M
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
SCSC
GERN
Price
$40.38
$1.39
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
$43.00
$3.00
AVG Volume (30 Days)
158.6K
9.1M
Earning Date
02-05-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
1.79
N/A
EPS
3.20
N/A
Revenue
$3,004,880,000.00
$183,403,000.00
Revenue This Year
$5.40
$147.42
Revenue Next Year
$5.34
$37.07
P/E Ratio
$12.73
N/A
Revenue Growth
N/A
522.13
52 Week Low
$28.75
$1.04
52 Week High
$51.66
$3.12

Technical Indicators

Market Signals
Indicator
SCSC
GERN
Relative Strength Index (RSI) 49.39 54.24
Support Level $39.34 $1.26
Resistance Level $41.78 $1.37
Average True Range (ATR) 1.08 0.08
MACD 0.09 -0.00
Stochastic Oscillator 53.46 52.27

Price Performance

Historical Comparison
SCSC
GERN

About SCSC ScanSource Inc.

ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: